Toripalimab was approved by the NMPA on December 17, 2018, for the treatment of unresectable or metastatic melanoma in patients who have previously received and failed systemic therapy; it is also approved for the treatment of recurrent or metastatic nasopharyngeal carcinoma in patients who have failed two or more lines of prior systemic therapy.